Gapping up
In reaction to strong earnings/guidance: GMCR +19.1%, GFI +15.7%, CTRP +12%, WB +8.4%, CRM +4.9%, CRH +4.6%, PERY +4%, NTAP +2.1%, SINA +1.9%, CVO +0.6%, SJM +0.5%
M&A news: CLDN +64.9% (Celladon and Eiger BioPharmaceuticals sign merger agreement; concurrent financing of $39.5 million from investor syndicate), BZC +3.5% (TransDigm Group Incorporated (TDG) and Breeze-Eastern agree to an acquisition of Breeze-Eastern for $19.61/share in cash)
Select small cap biotech related names showing strength: MCUR +32.5%, CAPN +20.8%, SPHS +8.9%, PHMD +3.6%, APPY +3.2%, ORMP +3%, SNTA +2.8%
Select metals/mining stocks trading higher: MTL +7.3%, AU +3.6%, MT +2.9%, BHP +1.7%, BBL +1.3%, RIO +1.2%, AA +1.1%, VALE +1%, GDX +0.6%
Other news: KBIO +663.8% (Former Retrophin CEO and current Turing Pharma CEO Martin Shkreli discloses ownership of ~1.625 mln shares; ~1.2 mln shares purchased from 11/16 to 11/17 at prices ranging from $0.30-2.45 per share ), STEM +53.8% (announces that the six-month interim results for the first cohort in its ongoing Phase II Pathway Study in cervical spinal cord injury showed motor improvements in both strength and function), NLST +51.5% (entered into a five year Joint Development and License Agreement w/ Samsung Electronics (SSNLF) to produce a new class of NVDIMM-P memory solutions), UNXL +34% (receives initial mass production order from Japanese PC manufacturer), VTAE +23.3% (announced positive top-line results from a Phase 1 multiple ascending dose trial of VTP-43742; shown to be safe and generally well tolerated in healthy human volunteers), SFXE +23.2% (light volume, pre-mkt rebound following yday's news), HART +21.9% (small cap biotech peer; CFO disclosed small purchase last night -- 10K shares), VTL +15.7% (received written responses from the FDA to its Type C meeting request on the planned VTL-308 phase 3 clinical trial), VBLT +13% (announces significant improvement of 12 Month overall survival with VB-111), TUMI +6.5% (to replace IPCM in the S&P SmallCap 600), PLPM +6.4% (signs multi-currency processing agreement with BBVA Bancomer and launches its integrated payments hospitality solution for BBVA Bancomer merchants ), ATHX +4% (reports that multipotent adult progenitor cells, used in its MultiStem cell therapy, are effective in improving the health of animals after acute rodent spinal cord injury), ZIOP +3.8% (will present initial results from its Phase 1 dose-escalation study of Ad-RTS-hIL-12), RTN +2.9% (affirms $0.67/share quarterly dividend, adds $2 bln to repurchase program ), FIT +2.4% (favorable commentary on Wednesday's Mad Money), CETV +2.3% (TCS Capital Management discloses 10.9% active stake in 13D filing; TCS sends letter to Board urging pursuit of strategic alternatives), CLLS +1.7% (Servier Exercises signs exclusive worldwide licensing option with Cellectis for UCART19), VOD +1.3% (announces its intention to raise around £500 million of new debt issuance of non-dilutive equity-linked bonds due 2020), DAL +1% (announces its intention to acquire up to an additional 32% of the outstanding capital stock of Grupo Aeromexico S.A.B. through a cash tender offer for MXP$43.59/share)
Analyst comments: TTPH +8.6% (upgraded to Buy from Neutral at Sun Trust Rbsn Humphrey), WEN +2.8% (added to Conviction Buy List at Goldman), NGG +1.4% (upgraded to Outperform at RBC Capital Mkts), SUN +1.3% (upgraded to Outperform from Neutral at Credit Suisse)
In reaction to strong earnings/guidance: GMCR +19.1%, GFI +15.7%, CTRP +12%, WB +8.4%, CRM +4.9%, CRH +4.6%, PERY +4%, NTAP +2.1%, SINA +1.9%, CVO +0.6%, SJM +0.5%
M&A news: CLDN +64.9% (Celladon and Eiger BioPharmaceuticals sign merger agreement; concurrent financing of $39.5 million from investor syndicate), BZC +3.5% (TransDigm Group Incorporated (TDG) and Breeze-Eastern agree to an acquisition of Breeze-Eastern for $19.61/share in cash)
Select small cap biotech related names showing strength: MCUR +32.5%, CAPN +20.8%, SPHS +8.9%, PHMD +3.6%, APPY +3.2%, ORMP +3%, SNTA +2.8%
Select metals/mining stocks trading higher: MTL +7.3%, AU +3.6%, MT +2.9%, BHP +1.7%, BBL +1.3%, RIO +1.2%, AA +1.1%, VALE +1%, GDX +0.6%
Other news: KBIO +663.8% (Former Retrophin CEO and current Turing Pharma CEO Martin Shkreli discloses ownership of ~1.625 mln shares; ~1.2 mln shares purchased from 11/16 to 11/17 at prices ranging from $0.30-2.45 per share ), STEM +53.8% (announces that the six-month interim results for the first cohort in its ongoing Phase II Pathway Study in cervical spinal cord injury showed motor improvements in both strength and function), NLST +51.5% (entered into a five year Joint Development and License Agreement w/ Samsung Electronics (SSNLF) to produce a new class of NVDIMM-P memory solutions), UNXL +34% (receives initial mass production order from Japanese PC manufacturer), VTAE +23.3% (announced positive top-line results from a Phase 1 multiple ascending dose trial of VTP-43742; shown to be safe and generally well tolerated in healthy human volunteers), SFXE +23.2% (light volume, pre-mkt rebound following yday's news), HART +21.9% (small cap biotech peer; CFO disclosed small purchase last night -- 10K shares), VTL +15.7% (received written responses from the FDA to its Type C meeting request on the planned VTL-308 phase 3 clinical trial), VBLT +13% (announces significant improvement of 12 Month overall survival with VB-111), TUMI +6.5% (to replace IPCM in the S&P SmallCap 600), PLPM +6.4% (signs multi-currency processing agreement with BBVA Bancomer and launches its integrated payments hospitality solution for BBVA Bancomer merchants ), ATHX +4% (reports that multipotent adult progenitor cells, used in its MultiStem cell therapy, are effective in improving the health of animals after acute rodent spinal cord injury), ZIOP +3.8% (will present initial results from its Phase 1 dose-escalation study of Ad-RTS-hIL-12), RTN +2.9% (affirms $0.67/share quarterly dividend, adds $2 bln to repurchase program ), FIT +2.4% (favorable commentary on Wednesday's Mad Money), CETV +2.3% (TCS Capital Management discloses 10.9% active stake in 13D filing; TCS sends letter to Board urging pursuit of strategic alternatives), CLLS +1.7% (Servier Exercises signs exclusive worldwide licensing option with Cellectis for UCART19), VOD +1.3% (announces its intention to raise around £500 million of new debt issuance of non-dilutive equity-linked bonds due 2020), DAL +1% (announces its intention to acquire up to an additional 32% of the outstanding capital stock of Grupo Aeromexico S.A.B. through a cash tender offer for MXP$43.59/share)
Analyst comments: TTPH +8.6% (upgraded to Buy from Neutral at Sun Trust Rbsn Humphrey), WEN +2.8% (added to Conviction Buy List at Goldman), NGG +1.4% (upgraded to Outperform at RBC Capital Mkts), SUN +1.3% (upgraded to Outperform from Neutral at Credit Suisse)